Systemic nonarticular manifestations of rheumatoid arthritis: focus on inflammatory mechanisms.

[1]  M. Irwin,et al.  Chronic stress and regulation of cellular markers of inflammation in rheumatoid arthritis: Implications for fatigue , 2008, Brain, Behavior, and Immunity.

[2]  Mahboob Rahman,et al.  Association of anemia and physical disability among patients with rheumatoid arthritis. , 2007, The Journal of rheumatology.

[3]  A. Silman,et al.  Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register , 2007, Arthritis and rheumatism.

[4]  E. Karlson,et al.  Antioxidants and other novel cardiovascular risk factors in subjects with rheumatoid arthritis in a large population sample. , 2007, Arthritis and rheumatism.

[5]  P. Garnero,et al.  Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis , 2007, Annals of the rheumatic diseases.

[6]  B. Dijkmans,et al.  Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis , 2007, Annals of the rheumatic diseases.

[7]  Y. Shoenfeld,et al.  Precocious Atherosclerosis in Rheumatoid Arthritis , 2007, Annals of the New York Academy of Sciences.

[8]  S. Gabriel,et al.  Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? , 2007, Annals of the rheumatic diseases.

[9]  M. Suarez‐Almazor,et al.  Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. , 2007, The Journal of rheumatology.

[10]  T. Yoshikawa,et al.  A case report of tumor necrosis factor-alpha antibody-induced thrombocytopenia associated with emerging IgM anticardiolipin antibody in patients with scleroderma overlap/rheumatoid arthritis , 2007, Clinical Rheumatology.

[11]  J. Kirwan,et al.  Measuring fatigue in rheumatoid arthritis: a systematic review of scales in use. , 2007, Arthritis and rheumatism.

[12]  Kozo Nakamura,et al.  Scientific basis for the efficacy of combined use of antirheumatic drugs against bone destruction in rheumatoid arthritis , 2007, Modern rheumatology.

[13]  B. Tomlinson,et al.  Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis , 2007, Clinical Rheumatology.

[14]  F. Wolfe,et al.  Rheumatoid arthritis treatment and the risk of severe interstitial lung disease , 2007, Scandinavian journal of rheumatology.

[15]  R. Bell,et al.  Rheumatoid arthritis-associated necrotizing scleritis and peripheral ulcerative keratitis treated successfully with infliximab. , 2006, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[16]  Y. Kadono,et al.  Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction , 2006, The Journal of experimental medicine.

[17]  C. Heycock,et al.  TNFα blocker-induced thrombocytopenia , 2006 .

[18]  B. Dijkmans,et al.  Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study , 2006, Arthritis research & therapy.

[19]  P. Emery,et al.  Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. , 2006, Arthritis and rheumatism.

[20]  C. Mancuso,et al.  Psychosocial variables and fatigue: a longitudinal study comparing individuals with rheumatoid arthritis and healthy controls. , 2006, The Journal of rheumatology.

[21]  F. Wolfe,et al.  Anemia and renal function in patients with rheumatoid arthritis. , 2006, The Journal of rheumatology.

[22]  C. Turesson,et al.  Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis , 2006, Annals of the rheumatic diseases.

[23]  E. Choy,et al.  Fatigue in rheumatoid arthritis reflects pain, not disease activity. , 2006, Rheumatology.

[24]  M. Cutolo,et al.  Effects of Anti‐TNF‐α Treatment on Lipid Profile in Patients with Active Rheumatoid Arthritis , 2006 .

[25]  M. Genovese,et al.  Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[26]  D. Borderie,et al.  Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[27]  Richard B Devereux,et al.  Preclinical Carotid Atherosclerosis in Patients with Rheumatoid Arthritis , 2006, Annals of Internal Medicine.

[28]  C. Turesson,et al.  Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia. , 2006, Arthritis and rheumatism.

[29]  C. Turesson,et al.  Incidence of noncardiac vascular disease in rheumatoid arthritis and relationship to extraarticular disease manifestations. , 2006, Arthritis and rheumatism.

[30]  C. Selinger,et al.  MCP-1-induced Human Osteoclast-like Cells Are Tartrate-resistant Acid Phosphatase, NFATc1, and Calcitonin Receptor-positive but Require Receptor Activator of NFκB Ligand for Bone Resorption* , 2006, Journal of Biological Chemistry.

[31]  Hyon K. Choi,et al.  Lipid profiles among US elderly with untreated rheumatoid arthritis--the Third National Health and Nutrition Examination Survey. , 2005, The Journal of rheumatology.

[32]  S. Yoshino,et al.  Correlation between dry eye and rheumatoid arthritis activity. , 2005, American journal of ophthalmology.

[33]  A. Hassell,et al.  Anemia in rheumatoid arthritis: association with polymorphism in the tumor necrosis factor receptor I and II genes. , 2005, The Journal of rheumatology.

[34]  M. Danacı,et al.  Pulmonary involvement in rheumatoid arthritis , 2005, Rheumatology International.

[35]  C. Turesson,et al.  Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. , 2005, The Journal of rheumatology.

[36]  S. Genevay,et al.  Etanercept in treatment of Felty’s syndrome , 2005, Annals of the rheumatic diseases.

[37]  Pereira da Silva,et al.  Inflammatory cell infiltrate and RANKL/OPG expression in rheumatoid synovium: comparison with other inflammatory arthropathies and correlation with outcome. , 2005, Clinical and experimental rheumatology.

[38]  X. Mariette,et al.  Lack of efficacy of rituximab in Felty’s syndrome , 2005, Annals of the rheumatic diseases.

[39]  F. Wolfe,et al.  Fatigue, rheumatoid arthritis, and anti-tumor necrosis factor therapy: an investigation in 24,831 patients. , 2004, The Journal of rheumatology.

[40]  A. Corrado,et al.  TNF-α antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis , 2004 .

[41]  C. Trautwein,et al.  Mechanisms of Disease: the role of hepcidin in iron homeostasis—implications for hemochromatosis and other disorders , 2004, Nature Clinical Practice Gastroenterology &Hepatology.

[42]  B. Joffe,et al.  Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis , 2004, Arthritis research & therapy.

[43]  S. Goldring,et al.  Adverse effects of rheumatoid arthritis on bone remodeling , 2004, Arthritis Research & Therapy.

[44]  M. Netea,et al.  Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis , 2004, Annals of the rheumatic diseases.

[45]  Olof Johnell,et al.  A Meta‐Analysis of Prior Corticosteroid Use and Fracture Risk , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[46]  Elizabeta Nemeth,et al.  IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. , 2004, The Journal of clinical investigation.

[47]  L. Moreland,et al.  A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate , 2004, Annals of the rheumatic diseases.

[48]  A. Nissenson,et al.  Prevalence and outcomes of anemia in rheumatoid arthritis: a systematic review of the literature. , 2004, The American journal of medicine.

[49]  C. Turesson,et al.  Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study , 2004, Annals of the rheumatic diseases.

[50]  C. Maury,et al.  Tumor necrosis factor alpha, its soluble receptor I, and -308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis: implications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis. , 2003, Arthritis and rheumatism.

[51]  S. van der Linden,et al.  Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis , 2003, Annals of the rheumatic diseases.

[52]  S. Gabriel,et al.  Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years , 2003, Annals of the rheumatic diseases.

[53]  U. Pleyer,et al.  Tumour necrosis factor alpha and interleukin 6 gene expression in keratocytes from patients with rheumatoid corneal ulcerations , 2003, The British journal of ophthalmology.

[54]  N. Athanasou,et al.  Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. , 2002, Bone.

[55]  M. Loda,et al.  Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. , 2002, Blood.

[56]  F. Ruschitzka,et al.  Anti–Tumor Necrosis Factor-α Treatment Improves Endothelial Function in Patients With Rheumatoid Arthritis , 2002 .

[57]  S. Abramson,et al.  Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. , 2002, Rheumatology.

[58]  H. Papadaki,et al.  Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-alpha antibody therapy. , 2002, Blood.

[59]  G L Freeman,et al.  High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. , 2001, Arthritis and rheumatism.

[60]  A. Siegbahn,et al.  Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. , 2001, JAMA.

[61]  G. Stucki,et al.  Effect of recombinant human erythropoietin and intravenous iron on anemia and disease activity in rheumatoid arthritis. , 2001, The Journal of rheumatology.

[62]  E. Hay,et al.  Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice. , 2001, QJM : monthly journal of the Association of Physicians.

[63]  P. Ridker,et al.  Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. , 2000, Circulation.

[64]  S. Humphries,et al.  Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? , 2000, Atherosclerosis.

[65]  P. Voulgari,et al.  Role of cytokines in the pathogenesis of anemia of chronic disease in rheumatoid arthritis. , 1999, Clinical immunology.

[66]  C. Turesson,et al.  Extra-articular rheumatoid arthritis: prevalence and mortality. , 1999, Rheumatology.

[67]  O Wiegman,et al.  Fatigue in rheumatoid arthritis: the role of self-efficacy and problematic social support. , 1998, British journal of rheumatology.

[68]  M. Jongen‐Lavrencic,et al.  Elevated levels of inflammatory cytokines in bone marrow of patients with rheumatoid arthritis and anemia of chronic disease. , 1997, The Journal of rheumatology.

[69]  J. Lanchbury,et al.  T cell receptor α-chain and β-chain junctional region homology in clonal CD3+,CD8+ T lymphocyte expansions in Felty's syndrome , 1997 .

[70]  M. Tryba.  Epoetin alfa plus autologous blood donation in patients with a low hematocrit scheduled to undergo orthopedic surgery. , 1996, Seminars in hematology.

[71]  F. Mercuriali.  Epoetin alfa for autologous blood donation in patients with rheumatoid arthritis and concomitant anemia. , 1996, Seminars in hematology.

[72]  R. Rau,et al.  Thrombocytopenia in patients with rheumatoid arthritis on long-term treatment with low dose methotrexate , 1996, Clinical Rheumatology.

[73]  G. Kingsley,et al.  The role of interleukin-8 and other cytokines in the pathogenesis of Felty's syndrome. , 1995, Clinical and experimental rheumatology.

[74]  J. Anaya,et al.  Pulmonary involvement in rheumatoid arthritis. , 1995, Seminars in arthritis and rheumatism.

[75]  K. Chan,et al.  Extra-articular manifestations are uncommon in southern Chinese with rheumatoid arthritis. , 1993, British journal of rheumatology.

[76]  J. Symons,et al.  CORRELATION OF PLASMA INTERLEUKIN 1 LEVELS WITH DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS , 1988, The Lancet.

[77]  M. Piazza,et al.  HEPATITIS B NOT TRANSMISSIBLE VIA FÆCAL-ORAL ROUTE , 1975, The Lancet.

[78]  C. Turesson,et al.  Increased CD4+ T cell infiltrates in rheumatoid arthritis-associated interstitial pneumonitis compared with idiopathic interstitial pneumonitis. , 2005, Arthritis and rheumatism.

[79]  S. Gabriel,et al.  Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. , 2003, Arthritis and rheumatism.

[80]  M. Weisman,et al.  Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. , 2003, Arthritis and rheumatism.

[81]  S. Gabriel,et al.  Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. , 2002, The Journal of rheumatology.